Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and ...
Integrating HER2-directed therapies into NSCLC decision-making requires adapting protocols and ensuring timely updates as new therapies emerge. Streamlined processes and enhanced communication among ...
Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The ...
I was 18 when my mom was diagnosed with breast cancer. It altered the trajectory of my second year at college and changed how I viewed my mom, whom I naively thought was exempt from harm. She knew ...
The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...
Eleven years after my mother died in 1994, when I was 31, I learned that a simple blood test could confirm whether I was a carrier of a BRCA gene mutation. Named for the first two letters of "breast" ...
Scientists at the Victor Chang Cardiac Research Institute, working with colleagues at the Vanderbilt University Medical Center, have developed a world-first, individualized risk prediction tool for ...
Scientists at the Victor Chang Cardiac Research Institute have developed a world-first individualised risk prediction tool for people suffering from a type of heart arrhythmia that can cause sudden ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results